Findings

What do systematic reviews say?

8 questions · 8 findings · 2 reviews

No studies found 2 · 25%GRADE not reported 0 · 0%Very low 0 · 0%Low 1 · 12.5%Moderate 5 · 62.5%High 0 · 0%

Fistulae thromboses (up to 1 month) · people with ESRD receiving haemodialysis through an arteriovenous fistula or graft

Ticlopidine probably leads to lower fistulae thromboses (up to 1 month) compared with placebo (moderate certainty).

1 finding from 1 review

Medical adjuvant treatment to increase patency of arteriovenous fistulae and grafts 2021 · Cochrane Headline outcomes only
OR 0.45 [0.25, 0.82]
3 studies · 339 participants
Moderate

Length of hospital stay · people with ESRD receiving haemodialysis through an arteriovenous fistula or graft

The review found no eligible studies for this question.

1 finding from 1 review

Medical adjuvant treatment to increase patency of arteriovenous fistulae and grafts 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Complications (up to 1 month) · people with ESRD receiving haemodialysis through an arteriovenous fistula or graft

1 finding from 1 review

Medical adjuvant treatment to increase patency of arteriovenous fistulae and grafts 2021 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 339 participants
Low

Number of related surgical or radiological interventions · people with ESRD receiving haemodialysis through an arteriovenous fistula or graft

The review found no eligible studies for this question.

1 finding from 1 review

Medical adjuvant treatment to increase patency of arteriovenous fistulae and grafts 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

All‐cause mortality (ticlopidine vs placebo) · patients with type 2 diabetes mellitus

The intervention showed no clear difference in all‐cause mortality (ticlopidine vs placebo) (moderate certainty).

1 finding from 1 review

Vascular mortality (ticlopidine vs placebo) · patients with type 2 diabetes mellitus

The intervention showed no clear difference in vascular mortality (ticlopidine vs placebo) (moderate certainty).

1 finding from 1 review

Myocardial infarction (fatal and non‐fatal) (ticlopidine vs placebo) · patients with type 2 diabetes mellitus

The intervention showed no clear difference in myocardial infarction (fatal and non‐fatal) (ticlopidine vs placebo) (moderate certainty).

1 finding from 1 review

Stroke (fatal and non‐fatal) (a. ticlopidine vs aspirin) (b. clopidogrel vs aspirin & dipyramidole) · patients with type 2 diabetes mellitus

The intervention probably leads to lower stroke (fatal and non‐fatal) (a. ticlopidine vs aspirin) (b.… (moderate certainty).

1 finding from 1 review